Our therapeutic solutions

Making the fight against cancer our priority

Image
caring for cancer

Recognized expertise

The objective of our cancer research is to improve the treatment of patients suffering from pathologies for which there are significant unmet therapeutic needs, always staying true to the group's values, and with the objective of contributing to the better-being of individuals.

Pierre Fabre provides therapeutic solutions to treat different types of cancer:

  • MELANOMA by oral targeted therapy
  • LUNG CANCER by intravenous or oral chemotherapy
  • BREAST CANCER by intravenous, oral chemotherapy, or oral targeted therapy
  • BLADDER CANCER by intravenous chemotherapy
  • COLORECTAL CANCER by oral targeted therapy

Our oncology R&D strategy is multifaceted. Our focus is on developing innovative assets and using ground-breaking technologies to develop new treatments, while tapping into our expertise in targeted biotherapies. In 2015, we were looking to expand further into dermato-oncology and oncology, and the partnership opportunity with Array BioPharma (now in partnership with Pfizer) to develop BRAFTOVI and MEKTOVI in 

Europe, Turkey and Asia Pacific countries, fits both our interest and areas of expertise.  Through our partnership with PUMA Biotechnology, Pierre Fabre is committed to providing access to NERLYNX to people with HER2-positive breast cancer throughout Europe and in several additional territories (including Turkey, Middle East, Africa and Asia Pacific countries). 

 

Our oncology products

BRAFTOVI

(encorafenib)

Image
BRAFTOVI (encorafenib)
BRAFTOVI (encorafenib) is a BRAF kinase inhibitor, indicated in combination with MEKTOVI (binimetinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation.  
In association with cetuximab, BRAFTOVI is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAFV600E mutation, who have received prior systemic therapy. 
See EU Product Information
BRAFTOVI mCRC Product website (This website is dedicated to European Healthcare Professionals only)
 JAVLOR
(vinflunine)
Image
 JAVLOR (vinflunine)
JAVLOR (vinflunine) is an antineoplasic agent indicated in monotherapy for the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract, after failure of a prior platinum-containing regimen.
Efficacy and safety of vinflunine have not been studied in patients with performance status >=2. 
See EU Product Information

MEKTOVI

(binimetinib)

Image
MEKTOVI (binimetinib)
MEKTOVI (binimetinib) is a proteine kinase inhibitor indicated in combination with BRAFTOVI (encorafenib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation. 
See EU Product Information
NAVELBINE IV
(vinorelbine)
Image
NAVELBINE IV
NAVELBINE IV (vinorelbine) is an antineoplasic agent indicated for the treatment of Advanced Breast Cancer and Non-Small Cell Lung Cancer.
NAVELBINE Oral
(vinorelbine)
Image
NAVELBINE Oral
NAVELBINE oral (vinorelbine) is an antineoplasic agent indicated for the treatment of Advanced Breast Cancer and Non-Small Cell Lung Cancer.

NERLYNX

(neratinib)

Image
NERLYNX
NERLYNX (neratinib) is an oral pan-HER irreversible tyrosine kinase inhibitor, indicated in the European Union for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago. 
In China, NERLYNX is indicated as extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (HER2) positive breast cancer, to follow adjuvant trastuzumab-based therapy.
See EU Product Information
NERLYNX Product website (This website is dedicated to European Healthcare Professionals only)

These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

This international website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information  which may not comply with any legal process, regulation, registration or usage in the country of your origin.

 

 

0

NAVELBINE IV is registered in France

Image
oncopole recherche
0

Launch of NAVELBINE oral

Image
oncopole site
0

Launch of JAVLOR

Image
oncopole recherche
0

Opening of the Oncopole Research and Development Center

Image
patient aide reponses therapeutiques
0

EU Marketing authorization for NERLYNX in Breast Cancer and BRAFTOVI+MEKTOVI in Melanoma

Image
oncopole recherche
0

EU Marketing authorization for BRAFTOVI in Colorectal Cancer

Image
oncopole site

Oncopole, together against cancer

We are proud to be part of the Oncopole cluster in Toulouse, France, a ‘one-of-a-kind’ hub dedicated solely to fighting cancer. Through Oncopole, Pierre Fabre is part of an ecosystem of clinicians, patients, biotechs and researchers. 

A chair to drive progress in personalized medicine: 

The Toulouse Cancer Health Foundation, INSERM and the Pierre Fabre Research Institute (major players on the Toulouse Oncopole campus) have created the first chair in oncology bioinformatics for immuno-oncology research. Vera Pancaldi, a physicist expert in systems biology, took on the role on 3 September 2018 at the Cancer Research Centre of Toulouse.

Image
recherche oncopole

Innovating together against cancer

We have always favored a partnership-based approach to research, convinced that complementarity and the sharing of expertise are accelerators of innovation